Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RATIONAL-PT: Interventions to Prevent Infection in Blood Cancers
NCT07202052Phase 3Recruiting
- Sponsor
- Monash University
- Start
- May 2025
- Primary completion
- Mar 2027
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of intravenous immunoglobulin G in Infection (7 arms), sponsored by Monash University. Primary endpoint: Event-free survival at 12 months. Started May 2025; status: recruiting.
02
Drugs
intravenous immunoglobulin G
03
Conditions
Infection
Beyond the preview
Go deeper on NCT07202052.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07202052.